Leadership Overview
Azurity Pharmaceuticals has 5 executives leading key functions including strategy, finance, technology, operations, and human capital.
Driven by a commitment to patient well-being, Azurity Pharmaceuticals focuses on developing and delivering high-quality medicines for underserved populations, leveraging advanced commercial strategies to improve patient outcomes and address unmet medical needs globally.
Driven by a commitment to patient well-being, Azurity Pharmaceuticals focuses on developing and delivering high-quality medicines for underserved populations, leveraging advanced commercial strategies to improve patient outcomes and address unmet medical needs globally.
Leadership Roles at Azurity Pharmaceuticals
William Collins - Chief Executive Officer
William Collins, the Chief Executive Officer at Azurity Pharmaceuticals, directs the company's overall strategy and operational execution. Collins guides the organization's mission to develop and deliver innovative, high-quality medicines for underserved patients. Overseeing diverse therapeutic areas and dosage forms, the Chief Executive Officer ensures the effective deployment of advanced commercial strategies, data analytics, and digital tools. This leadership focuses on enhancing market reach and patient engagement to achieve improved health outcomes. William Collins drives the company's commitment to addressing unmet medical needs on a global scale, fostering a culture of innovation and patient-centricity. The Chief Executive Officer's purview encompasses all facets of the business, from research and development pipeline prioritization to market access and long-term financial health, ensuring Azurity Pharmaceuticals maintains its position as a key player in the biopharmaceutical sector.
Tom Oneil - Chief Financial Officer
Tom Oneil, the Chief Financial Officer at Azurity Pharmaceuticals, manages the company's financial operations and strategic fiscal planning. Oneil oversees all aspects of financial reporting, budgeting, forecasting, and capital allocation, ensuring robust financial health and sustainable growth. The Chief Financial Officer plays a critical role in evaluating investment opportunities, managing investor relations, and optimizing the company's capital structure to support its mission of delivering innovative medicines. Tom Oneil's financial acumen is essential for navigating the complex economic landscape of the biopharmaceutical industry, driving efficiency across departments. This leadership position involves close collaboration with other executives to align financial strategies with the company's overarching goals of improving patient outcomes and addressing unmet medical needs. The Chief Financial Officer ensures compliance with all financial regulations and drives initiatives to enhance profitability and shareholder value.
Elad Sasson - Deputy Chief Technology Officer
Elad Sasson, the Deputy Chief Technology Officer at Azurity Pharmaceuticals, supports the strategic direction and implementation of the company's technology initiatives. Sasson focuses on leveraging advanced digital tools and data analytics to enhance Azurity Pharmaceuticals' commercial strategies and operational efficiency. The Deputy Chief Technology Officer plays a key part in optimizing the company's technological infrastructure to support the development and delivery of high-quality medicines for underserved patients. Elad Sasson's expertise contributes to improving market reach and patient engagement through innovative technological solutions. This role involves collaborating with cross-functional teams to ensure technology adoption aligns with the company's mission of addressing unmet medical needs globally. The Deputy Chief Technology Officer drives the integration of cutting-edge technologies to streamline processes and enhance data-driven decision-making across the organization.
Jordan Lilly - Chief of Staff & Project Management Office Vice President, Enterprise (Epmo)
Jordan Lilly, the Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) at Azurity Pharmaceuticals, orchestrates critical strategic initiatives and oversees the enterprise project management office. Lilly ensures seamless execution of complex projects, aligning departmental efforts with the company's core objectives of delivering innovative medicines to underserved patients. The Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) facilitates effective communication and collaboration across leadership teams, driving operational excellence and strategic alignment. Jordan Lilly's role is pivotal in enhancing the company's commercial strategies and leveraging data and digital tools to improve patient outcomes. This leadership function supports the company's mission to address unmet medical needs globally by ensuring efficient resource allocation and timely project completion. Jordan Lilly drives the strategic implementation of project management best practices, fostering a culture of accountability and continuous improvement within the enterprise.
Peter Dyke - Chief People Officer
Peter Dyke, the Chief People Officer at Azurity Pharmaceuticals, leads the human capital strategy, fostering a culture that supports the company's mission of delivering innovative medicines. Dyke oversees all aspects of talent management, organizational development, and employee engagement, ensuring Azurity Pharmaceuticals attracts and retains top talent. The Chief People Officer plays a vital role in aligning people strategies with the company's advanced commercial approaches and digital initiatives, aiming to enhance patient outcomes. Peter Dyke's leadership focuses on building a high-performing workforce capable of addressing unmet medical needs globally. This executive function ensures a supportive and dynamic work environment, crucial for driving innovation in the biopharmaceutical sector. The Chief People Officer champions initiatives that promote employee well-being, professional growth, and a strong sense of purpose aligned with the company's patient-centric values.
Explore Leadership Teams in Manufacturing
Founded in 1951, Cadila Pharmaceuticals is a privately held pharmaceutical company in India. The company's integrated operations cover the entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products, and pharmaceutical Machinery.
Company Leadership AT
SB
DA
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
SG
SP
CS
Founded in 1994 and headquartered in Shanghai, China, Fosun Pharma is a company that focuses on the research and development and manufacturing of pharmaceuticals.
Company Leadership AD
AH
YS
LC
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.
Company Leadership VK
MM
GA
Frequently Asked Questions Regarding Azurity Pharmaceuticals Top Executives and Leadership Team
